Comparative analysis of drug revolving fund (DRF) and public private partnership (PPP) program on drug supply management in University college hospital (UCH), Ibadan, Nigeria
Main Article Content
Abstract
Background: Financing drugs supply through DRF was adopted at UCH, Ibadan from 1988 until 2005, when it was reverted to PPP whereby partnership in healthcare provisioning was emphasized.
Objectives: This study was aimed at comparing the two models and how the National Drug Policy goals have been achieved.
Method: Pharmacy stock records were analyzed while questionnaire was administered to outpatients. Interviews were also conducted for pharmacists with in-depth information of the two models.
Results: Records revealed that availability of the tracer drugs was more consistent during the PPP than DRF. Patronage was high (86.9%), yet patients complained of non-availability of essential drugs as they still patronize community pharmacies to fill their prescriptions. Generally, the selling prices of the drugs were higher than that of community pharmacy.
Respondents at interviews opine that fast-moving and profit-oriented drugs were the focus of PPP which seemingly undermined quality as opposed to essential and orphan drugs of DRF. Respondents preferred DRF to PPP based on sustainability and recommended reversion to it.
Conclusion: It was concluded that drug subsidy via health insurance scheme should be given priority by government. Revitalized supply through tender in DRF will reduce stock-outs and high cost of drugs. Furthermore, all relevant stakeholders should be involved in the planning and implementation of any program adopted and proper coordination is paramount for success and sustainability.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
FMOH/ WHO (2005). National Drug Policy (NDP), First Revision, 2003. Nigeria Federal Ministry of Health Production, pp.4-17.
WHO (1998). Drug Supplies Choices: what works best? Essential Drug Monitor (EDM) 025-026: 7-9
WHO (1998). Health Reform and Drug Financing in Action Programme on Essential Drugs. Essential Drug Monitor (EDM) 025-026:2
FMOH /WHO (2010). Indepth Assessment of Procurement and Supply Management Systems for Medical Products. Printed in Nigeria pp.5-12
FMOH/WHO (2002). Baseline Assessment of the Nigeria Pharmaceutical Sector. Nigeria, Federal Ministry of Health Production, pp.5
PATHS and DFID (2009). Technical Brief on Strengthening Sustainable Drug Supply Systems, pp.2-3
Gilson L. (1997). The lessons of user fee experience in Africa. Health Policy and Planning 12: 273-85.
Ridde V. (2011). Report from West Africa: is the Bamako Initiative still relevant for West African health systems. International Journal of Health Services 41(1):175–184
FMOH (2004).Revised National Health Policy (NHP), 1st revised ed. Abuja, Nigeria, pp. 2-6
FMOH (2005). National Policy on Public Private Partnership for Health in Nigeria. Nigeria, Federal Ministry of Health Production, pp. 7-8
MSH/WHO/DAP (1997). Management Sciences for Health/World Health Organization / Action Programme on Essential Drugs in Managing Drug Supply, 2nd ed. Hartford, C.T: Kumarian Press Inc. Cincinnati, pp.2-10
Dele Ogunyemi (2005). UCH Workers Protest Proposed Privatizations of Hospital Services. Daily Trust, 24 May, 2005,pp.14
FMOH (2005). Communiqué issued at the end of a 3-day National Consultative Workshop on Public Private Partnership in health in Nigeria held at the st Nicon Hotel, Abuja, March 30 – April 1 2005. Daily Trust, 6 June, 2005,pp.14
Uzochukwu B.SC., Onwujekwe O.E., & Akpala C.O. (2002). Effect of Bamako- Initiative Drug revolving fund on availability and rational use of essential drugs in primary health care facilities in south-east Nigeria. In Health Policy and Planning 17(4):378-383
WHO/HAI (2008). Measuring medicine prices, nd availability, affordability and price components 2 edition. Geneva, World Health Organization production, pp.1-7
Uzochukwu B. and Onwujekwe O. (2005). Healthcare reform involving the introduction of user fees and drug revolving funds: influence on
health workers' behaviour in southeast Nigeria. In Health Policy, Nigeria, vol.75 pp.1-8
Druce N., Kgatlwane J., Mosime O. and Ramiah I. (2004). Impact of Public-private Partnerships Addressing access to pharmaceuticals in Low and Middle Income Countries: Botswana. In Initiative on Public-Private Partnerships for Health (IPPPH), Global Forum for Health Research. Printed in Switzerland pp.32-34
WHO (1998). Editorial: Managing Drug Supply. Essential Drug Monitor (EDM) 025-026: 1